1 / 10

stroke prevention in patients with atrial fibrillation findings from the phase ii petro trial and ongoing phase iii re

At least as efficacious as current standard therapyAt least as safe as current standard therapyAvailable for oral administrationRequire no monitoringNo relevant interactions with food and common drugsCost-effective... in order to aid treatment compliance and avoid the serious consequences of thrombosis and bleeding.

libitha
Download Presentation

stroke prevention in patients with atrial fibrillation findings from the phase ii petro trial and ongoing phase iii re

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Stroke prevention in patients with atrial fibrillation – findings from the Phase II PETRO trial and ongoing Phase III RE-LY trial Lars Wallentin University Hospital, Uppsala, Sweden

    3. Key features of new oral anticoagulants

    4. PETRO: study design

    5. PETRO and PETRO-Ex: accumulated results

    6. Bear in mind only 408 patients at outset of dabigatran curve versus >6000 for ximelagatranBear in mind only 408 patients at outset of dabigatran curve versus >6000 for ximelagatran

    8. Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RE-LY Study) The RE-LY trial compares warfarin to two blinded doses of RENDIX™ (dabigatran etexilate) The trial has a randomization of 2:1 - 10,000 patients on RENDIX™ and 5,000 on warfarin Treatment will be open label with regards to warfarin however the two doses of RENDIX™ will be blinded Treatment duration will be up to three years with patients followed-up until the trial is closed (a follow-up range of 1-3 years) Patients are seen every 3-4 months The mean treatment period is 20-24 months Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RE-LY Study) The RE-LY trial compares warfarin to two blinded doses of RENDIX™ (dabigatran etexilate) The trial has a randomization of 2:1 - 10,000 patients on RENDIX™ and 5,000 on warfarin Treatment will be open label with regards to warfarin however the two doses of RENDIX™ will be blinded Treatment duration will be up to three years with patients followed-up until the trial is closed (a follow-up range of 1-3 years) Patients are seen every 3-4 months The mean treatment period is 20-24 months

    9. Conclusions on new anticoagulants in arterial thromboembolism

    10. RE-DEEM study – Dabigatran dose guiding in ACS

More Related